Immunovant (IMVT) Cash from Investing Activities (2019 - 2026)
Immunovant (IMVT) posted Cash from Investing Activities of -$8000.0 for Q1 2026, up 96.02% on a QoQ basis from -$201000.0 in Q1 2025, and up 96.02% year-over-year from -$4081.2 in Q1 2025.
Immunovant (IMVT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Immunovant's Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$8000.0 for Q1 2026.
- Quarterly Cash from Investing Activities rose 96.02% year-over-year to -$8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8000.0 (up 98.95% YoY) and the FY2026 annual result came in at -$8000.0, up 98.95% from the prior year.
- Cash from Investing Activities was -$8000.0 for Q1 2026 at Immunovant, up from -$201000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$8000.0 in Q1 2026 and bottomed at -$201000.0 in Q1 2025.
- A 5-year average of -$103000.0 and a median of -$108000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities sank 476.92% — and 2026, when it soared 96.02%.
- Immunovant's Cash from Investing Activities stood at -$98000.0 in 2022, then slumped by 33.67% to -$131000.0 in 2023, then plunged by 37.4% to -$180000.0 in 2024, then decreased by 11.67% to -$201000.0 in 2025, then surged by 96.02% to -$8000.0 in 2026.
- Business Quant data shows IMVT's Cash from Investing Activities at -$8000.0 in Q1 2026, -$201000.0 in Q1 2025, and -$180000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Immunovant | 7.32 Bn | 6.42 Bn | - | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Mar 31, 2026 | -8,000.00 |
| Mar 31, 2025 | -201,000.00 |
| Mar 31, 2025 | -201,000.00 |
| Dec 31, 2024 | -180,000.00 |
| Dec 31, 2024 | -180,000.00 |
| Sep 30, 2024 | -196,000.00 |
| Sep 30, 2024 | -196,000.00 |
| Jun 30, 2024 | -182,000.00 |
| Jun 30, 2024 | -182,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Mar 31, 2024 | -150,000.00 |
| Dec 31, 2023 | -131,000.00 |
| Dec 31, 2023 | -131,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Sep 30, 2023 | -34,000.00 |
| Jun 30, 2023 | -45,000.00 |
| Jun 30, 2023 | -45,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Mar 31, 2023 | -26,000.00 |